Skip to main content
Premium Trial:

Request an Annual Quote

In Brief This Week: PerkinElmer; GeneNews; Genomic Vision; and More

NEW YORK (GenomeWeb) – PerkinElmer this week declared a regular quarterly dividend of $.07 per share of common stock. The dividend is payable on November 10 to all shareholders of record at the close of business on October 14.

GeneNews said this week that pursuant to its capital commitment agreement with GEM Global Yield Fund, it has made its first draw down in the amount of C$51,803 ($39,683). In connection with the draw down, the firm issued 338,702 common shares to GEM at C$.153 per share, as well as 338,702 warrants, which have an exercise price of C$.50 per common share and may be exercised for five years. GeneNews also said it recently entered into a modified interim working capital loan agreement with a major shareholder, who is also a director of the company, to borrow an additional US$150,000, bringing the firm's total borrowings to US$550,000.

Genomic Vision reported this week that its total revenues for the first half of 2016 fell to €1.3 million from €1.4 million in H1 2015. The firm's net loss widened to €4.0 million from €2.2 million. However, product sales — which for the first time accounted for the majority of the company's revenues from sales — increased 55 percent to €273,000 from €176,000 the year before.

Caris Life Sciences announced this week that it has appointed the Cancer Therapy & Research Center of the University of Texas Health Science Center at San Antonio a center of excellence site in the Caris Centers of Excellence for Precision Medicine Network. As a member of the Caris network, the CTRC will help develop standards of care and best practices for integrating molecular profiling into clinical oncology practice.

Axol Bioscience said this week that it has signed a collaboration agreement with Metrion Biosciences to improve, standardize, and more accurately predict the risk of human clinical pro-arrhythmias. Metrion will use Axol's human iPSC-derived cardiomyocytes to carry out ion channel screening, cardiac safety testing, and translational phenotypic assays.

Conversant Bio announced this week that it has partnered with Streck to offer circulating tumor DNA blood samples to cancer researchers.


In Brief This Week is a selection of news items that may be of interest to our readers but had not previously appeared on the GenomeWeb site.